Correlation Between 23Andme Holding and Sangamo Therapeutics
Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Sangamo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Sangamo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 23Andme Holding Co and Sangamo Therapeutics, you can compare the effects of market volatilities on 23Andme Holding and Sangamo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Sangamo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Sangamo Therapeutics.
Diversification Opportunities for 23Andme Holding and Sangamo Therapeutics
-0.77 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between 23Andme and Sangamo is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Sangamo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sangamo Therapeutics and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Sangamo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sangamo Therapeutics has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Sangamo Therapeutics go up and down completely randomly.
Pair Corralation between 23Andme Holding and Sangamo Therapeutics
Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to under-perform the Sangamo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, 23Andme Holding Co is 1.46 times less risky than Sangamo Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Sangamo Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 303.00 in Sangamo Therapeutics on October 1, 2024 and sell it today you would lose (47.00) from holding Sangamo Therapeutics or give up 15.51% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
23Andme Holding Co vs. Sangamo Therapeutics
Performance |
Timeline |
23Andme Holding |
Sangamo Therapeutics |
23Andme Holding and Sangamo Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with 23Andme Holding and Sangamo Therapeutics
The main advantage of trading using opposite 23Andme Holding and Sangamo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Sangamo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will offset losses from the drop in Sangamo Therapeutics' long position.23Andme Holding vs. IDEXX Laboratories | 23Andme Holding vs. Twist Bioscience Corp | 23Andme Holding vs. Guardant Health | 23Andme Holding vs. Agilent Technologies |
Sangamo Therapeutics vs. Editas Medicine | Sangamo Therapeutics vs. Intellia Therapeutics | Sangamo Therapeutics vs. Bluebird bio | Sangamo Therapeutics vs. Alnylam Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Complementary Tools
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Money Managers Screen money managers from public funds and ETFs managed around the world |